Elevation Oncology initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Elevation Oncology with a Buy rating and $1.50 price target. Oncology is focused on developing best possible select therapies for cancer, the analyst tells investors in a research note. The firm believes the shares at current levels offer an attractive opportunity for a long-term investor. It says antibody drug conjugate “could be a game changer.”